Imovax Rabies market seen growing on rising cases and pet ownership

The Business Research Company says the global Imovax Rabies market is set to expand through 2035 as rabies cases rise, pet ownership grows and vaccination programs widen. North America held the largest share in 2025, while the firm points to stronger demand for pre- and post-exposure vaccines worldwide.

Why it matters: - Rabies remains a fatal disease, so demand for preventive vaccines ties directly to public health and emergency response. - Growth in the Imovax Rabies market signals more use of pre-exposure and post-exposure vaccination in humans and animals. - The report frames vaccine access, travel patterns and government vaccination rules as key factors shaping global demand.

What happened: - The Business Research Company published its Competitive Landscape of the Imovax Rabies Global Market Report 2026 on Nov. 5, 2026. - The report covers market size, trends and forecasts for 2026-2035. - The company says North America held the largest share of the Imovax Rabies market in 2025. - The report includes Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional analysis. - The company also released a free sample of the report and a full report page.

The details: - Imovax Rabies is an inactivated vaccine used to prevent rabies infection in humans. - The vaccine is given as a series of intramuscular injections. - It is used as pre-exposure prophylaxis for people at high risk and as post-exposure prophylaxis after possible contact with a rabid or suspect animal. - The vaccine works by stimulating the immune system to produce protective antibodies. - The report says the market has grown historically because of rabies’ high fatality rate, frequent animal bites, early vaccine development, public immunization campaigns and hospital vaccination protocols. - The report expects future growth from more travel to rabies-endemic areas, expansion of veterinary public health programs, better vaccine availability in developing countries, higher preventive-care awareness and stricter government mandates. - The company identifies rising demand for rabies vaccines, wider pre-exposure immunization programs, broader post-exposure prophylaxis use and stronger global prevention efforts as key trends. - The report links market growth to rising rabies cases worldwide, driven by more contact with infected animals, low pet vaccination rates and limited access to timely treatment in some regions. - In April 2024, the South Dakota Department of Health reported a 122% increase in confirmed rabies cases in animals in 2023 compared with 2022. - The report also cites growing animal-related activities, including research, experimentation, breeding and genetic modification. - The U.S. Bureau of Labor Statistics said in August 2025 that employment in animal care and service sectors is projected to grow 11% from 2024 to 2034, with about 81,700 annual average job openings. - The report says rising pet ownership is another demand driver, supported by greater awareness of pet health and changing lifestyles. - The World Animal Foundation said in July 2025 that dog adoption rose from 56% in 2023 to 57% in 2024, while cat adoption rose from 62% to 64%. - The company’s 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The market story is less about one vaccine brand and more about the broader push to prevent rabies before exposure becomes an emergency. - The report’s focus on public health policy, veterinary programs and pet ownership suggests demand is being supported by both institutional and household behavior. - North America’s lead position in 2025 may reflect stronger access to vaccination infrastructure and reporting systems, though the report does not break out the drivers in detail.

What's next: - The Business Research Company expects the market to keep expanding through 2035 as preventive vaccination programs widen and awareness increases. - More travel, stronger mandates and better access in developing markets could add further demand for rabies vaccines. - The company is offering follow-up access through its marketing contacts and social channels, including LinkedIn and the company’s social media page.

The bottom line: - Imovax Rabies demand is being pulled by a mix of rising rabies risk, broader vaccination programs and expanding pet and animal-care activity.